We are live on ! Find out more
HP

HealthInvest Partners Portfolio holdings

AUM $372M
1-Year Est. Return 59.89%
This Fund
S&P 500
This Quarter Est. Return
+1.01%
1 Year Est. Return
+59.89%
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$164M
AUM Growth
-$349K
Cap. Flow
+$2.51M
Cap. Flow %
1.53%
Top 10 Hldgs %
67.19%
Holding
47
New
3
Increased
23
Reduced
11
Closed
9

Top Buys

Rank Stock Value
1
LLY icon
Eli Lilly
LLY
+$5.09M
2
UNH icon
UnitedHealth
UNH
+$4.23M
3
AMGN icon
Amgen
AMGN
+$2.56M
4
TMO icon
Thermo Fisher Scientific
TMO
+$2.45M
5
UFPT icon
UFP Technologies
UFPT
+$2.42M

Top Sells

Rank Stock Value
1
HRMY icon
Harmony Biosciences
HRMY
+$4.06M
2
ELV icon
Elevance Health
ELV
+$3.84M
3
GILD icon
Gilead Sciences
GILD
+$3.81M
4
FUSN
Fusion Pharmaceuticals Inc. Common Shares
FUSN
+$2.96M
5
NBIX icon
Neurocrine Biosciences
NBIX
+$2.72M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
LLY icon
1
Eli Lilly
LLY
$1T
$24.6M 14.98%
27,144
+6,366
+31% +$5.09M
UNH icon
2
UnitedHealth
UNH
$370B
$16.1M 9.84%
31,680
+8,639
+37% +$4.23M
MRK icon
3
Merck
MRK
$317B
$14M 8.51%
112,734
-21,007
-16% -$2.71M
TMO icon
4
Thermo Fisher Scientific
TMO
$210B
$10.8M 6.56%
19,458
+4,272
+28% +$2.45M
AMGN icon
5
Amgen
AMGN
$207B
$8.62M 5.26%
27,589
+8,698
+46% +$2.56M
BSX icon
6
Boston Scientific
BSX
$70.9B
$8.21M 5%
106,557
+29,156
+38% +$2.13M
REGN icon
7
Regeneron Pharmaceuticals
REGN
$78.1B
$7.24M 4.42%
6,893
+1,500
+28% +$1.45M
VRTX icon
8
Vertex Pharmaceuticals
VRTX
$122B
$7.08M 4.31%
15,095
+3,800
+34% +$1.65M
COR icon
9
Cencora
COR
$59.2B
$6.83M 4.17%
30,320
+9,894
+48% +$2.29M
SYK icon
10
Stryker
SYK
$129B
$6.8M 4.15%
19,983
+4,829
+32% +$1.64M
ABBV icon
11
AbbVie
ABBV
$434B
$6.11M 3.73%
35,618
+6,272
+21% +$1.04M
DXCM icon
12
DexCom
DXCM
$32.8B
$3.91M 2.38%
34,483
+8,200
+31% +$1.04M
EW icon
13
Edwards Lifesciences
EW
$51.3B
$3.37M 2.06%
36,505
+11,730
+47% +$1.04M
NBIX icon
14
Neurocrine Biosciences
NBIX
$17B
$3.25M 1.98%
23,630
-19,850
-46% -$2.72M
IQV icon
15
IQVIA
IQV
$37.8B
$2.96M 1.8%
13,984
+3,926
+39% +$892K
MOH icon
16
Molina Healthcare
MOH
$9.93B
$2.82M 1.72%
9,500
-2,500
-21% -$849K
CAH icon
17
Cardinal Health
CAH
$54.7B
$2.7M 1.65%
27,500
– –
UFPT icon
18
UFP Technologies
UFPT
$2.54B
$2.59M 1.58%
+9,800
New +$2.42M
MIRM icon
19
Mirum Pharmaceuticals
MIRM
$6.38B
$2.57M 1.57%
75,200
-47,800
-39% -$1.25M
ITCI
20
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$2.45M 1.5%
35,841
-2,209
-6% -$153K
IONS icon
21
Ionis Pharmaceuticals
IONS
$9.02B
$1.94M 1.18%
40,691
-23,100
-36% -$947K
MRUS
22
DELISTED
Merus
MRUS
$1.82M 1.11%
30,837
+6,512
+27% +$315K
CRBP icon
23
Corbus Pharmaceuticals
CRBP
$172M
$1.77M 1.08%
39,100
+1,100
+3% +$46.3K
ALKS icon
24
Alkermes
ALKS
$8.38B
$1.66M 1.01%
+68,800
New +$1.69M
OPCH icon
25
Option Care Health
OPCH
$3.5B
$1.51M 0.92%
54,395
-78,500
-59% -$2.34M
1
2

Similar funds

KP
Kiltearn Partners Edinburgh, United Kingdom $372M AUM 18.16% 1-Year Est. Return
TCM
Thomist Capital Management Houston, Texas $371M AUM 77.62% 1-Year Est. Return
SAAM
Solus Alternative Asset Management Summit, New Jersey $372M AUM 45.33% 1-Year Est. Return
PAA
Peregrine Asset Advisers Portland, Oregon $371M AUM 41.36% 1-Year Est. Return
PC
Promethos Capital Boston, Massachusetts $372M AUM 23.19% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
GIP
Gavilan Investment Partners Burlingame, California $372M AUM 6.04% 1-Year Est. Return
PC
Prevatt Capital Nassau, Bahamas $371M AUM 9.39% 1-Year Est. Return

HealthInvest Partners's Q2 2024 Portfolio in Review

As of Q2 2024, HealthInvest Partners held 47 positions worth $164M, down 0.21% from $164M the previous quarter. Its ten largest holdings account for 67% of the portfolio.

HealthInvest Partners's Q2 2024 filing shows 3 new, 23 increased, 11 reduced and 9 closed positions. Its largest new stake was UFP Technologies: 9,800 shares worth $2.59M. The largest sale was Harmony Biosciences, an estimated $4.06M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, unchanged from a quarter earlier.

  • HealthInvest Partners's largest Q2 2024 buy was UFP Technologies: 9,800 shares worth $2.59M.
  • HealthInvest Partners added most to Eli Lilly in Q2 2024, an estimated $5.09M increase.
  • HealthInvest Partners's biggest Q2 2024 reduction was Harmony Biosciences, cutting an estimated $4.06M.
  • HealthInvest Partners fully exited Elevance Health in Q2 2024, selling an estimated $3.84M.
  • HealthInvest Partners's ten largest holdings make up 67% of its $164M portfolio in Q2 2024.
  • HealthInvest Partners opened 3 new positions and closed 9 in Q2 2024.
  • HealthInvest Partners's portfolio value fell 0.21% quarter-over-quarter to $164M.

Based on HealthInvest Partners's 13F filing for Q2 2024, filed 14 Aug 2024.